We are monitoring the impact of COVID-19 on North America Lung Cancer Therapeutics Market Get in touch with us for detailed analysis Know More
Share on

North America Lung Cancer Therapeutics Market Research Report - Segmented By Treatment Type & Country (United States, Canada & Rest of North America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 834
Pages: 145

North America Lung Cancer Therapeutics Market Size (2022 to 2027)

The Lung Cancer Therapeutics Market size in North America is predicted to worth USD 2.95 billion by 2027 and USD 2.19 billion in 2022, growing at a CAGR of 6.14% during the forecast period. North America led the overall market in 2020 and was closely followed by the Asia Pacific.

Due to the rising prevalence of lung cancer, the market for lung cancer treatments is showing a promising CAGR, and this trend is likely to continue. Lung cancer patients in advanced stages still have a significant unmet demand for diagnosis and treatment. Tobacco smoking, the aging population, the availability of highly effective medicines, continuous asbestos exposure, and lifestyle factors are all potential drivers for the North American lung cancer therapeutics market. Lung cancer diagnoses have grown due to the introduction of new medical diagnostic equipment and advanced therapies, driving the lung cancer therapeutics market forward in North America. Increased development by key companies, robust R&D activities from major players, and expanding government initiatives for cancer awareness are some of the reasons driving market expansion.

Additionally, nanomedicine development to treat lung cancer and the increasing number of approvals in the lung cancer treatments market is fueling the industry's growth. Furthermore, factors such as focused and ground-breaking medication delivery to the lungs and the growing acceptance of customized therapies are considered significant drivers driving the lung cancer therapy industry. Breast cancer, lung cancer, prostate cancer, colorectum cancer, bladder cancer, and skin cancer are the most prevalent cancers in the United States. As a result, rising cancer incidence and increased research into targeted treatments are likely to drive Lung Cancer Therapeutic market expansion in the future years.

The North American lung cancer therapeutics market is constrained by a high unmet demand for diagnosis, the availability of a significant number of medicines, and restricted treatment choices. In addition, the lung cancer therapeutics market is also expected to be restrained by inadequate cancer diagnostic facilities in this region, high cost, and the side effects of radiation over the forecast period.

Chemotherapy and radiation treatment provides a greater risk of complications. The limited treatment options, widespread availability of generic critical medicines are expected to be the key challenges for the North American lung cancer therapeutics market growth. Although new medicines have boosted the lung cancer treatments market, patent expirations on existing drugs may have a negative impact on the Lung Cancer Therapeutic market in North America.

This research report on the North America Lung Cancer Therapeutics Market is segmented and sub-segmented into the following categories:

By Treatment Type:

  • Chemotherapy
    • Cisplatin
    • Taxol
    • Navelbine
    • Camptosar
    • Alimta
  • Radiotherapy
    • External Beam
    • Internal Beam
    • Systemic
  • Other Drugs
    • Abraxane
    • Avastin
    • Crizotinib
    • Docetaxel
    • Gefitinib

By Country:

  • United States
  • Canada
  • Rest of North America

Regionally, the United States is the dominating country for the lung cancer therapeutics market in terms of revenue, followed by Canada. Over the last few years, North America has dominated the Lung cancer treatments industry. Factors such as rising incidences of lung cancer and a growing senior population have contributed to the region's high demand. The significant rates of lung cancer in North America are also due to changing lifestyles with high smoking habits, which has resulted in a large pool of carcinoma lung population. Increased adoption of advanced lung cancer treatments and rising lung cancer prevalence and diagnosis are anticipated to fuel growth in the area. This is especially true in cases when a lack of appropriate therapy results in metastasis and, as a result, death.

KEY MARKET PLAYERS:

Companies playing a dominant role in the North America Lung Cancer Therapeutics Market profiled in this report are Boehringer Ingelheim GmbH, Hoffman-La Roche, Pfizer Inc., GlaxoSmithKline, Eli Lilly and Company, Agennix AG, AstraZeneca plc, and Sanofi-Aventis.

1. Introduction                                                 

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                           

                1.4 General Study Assumptions                                

2. Research Methodology                                                           

                2.1 Introduction                                              

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                            

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                     

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

3. Overview                                                      

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                      

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                               

5. Market Segmentation                                                              

                5.1 By Treatment Type                                 

                                5.1.1 Chemotherapy                     

                                                5.1.1.1 Cisplatin

                                                5.1.1.2 Taxol      

                                                5.1.1.3 Navelbine            

                                                5.1.1.4 Camptosar          

                                                5.1.1.5 Alimta   

                                5.1.2 Radiotherapy                         

                                                5.1.2.1 External Beam   

                                                5.1.2.2 Internal Beam    

                                                5.1.2.3 Systemic              

                                5.1.3 Other Drugs                            

                                                5.1.3.1 Abraxane             

                                                5.1.3.2 Avastin 

                                                5.1.3.3 Crizotinib             

                                                5.1.3.4 Docetaxel            

                                                5.1.3.5 Gefitinib               

6. Geographical Analysis                                                              

                6.1 Introduction                                              

                6.2 United States                                            

                6.3 Canada                                         

7. Pipeline Product Analysis                                                       

                7.1 Overview                                                    

                7.2 Pipeline Development Landscape                                                    

                7.3 Molecular Targets in the Pipeline                                                     

                7.4 Clinical Trials                                             

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target                       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                                  

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.                               

8. Strategic Analysis                                                       

                8.1 PESTLE analysis                                         

                                8.1.1 Political                     

                                8.1.2 Economic                 

                                8.1.3 Social                         

                                8.1.4 Technological                         

                                8.1.5 Legal                          

                                8.1.6 Environmental                      

                8.2 Porter’s Five analysis                                              

                                8.2.1 Bargaining Power of Suppliers                        

                                8.2.2 Bargaining Power of Consumers                    

                                8.2.3 Threat of New Entrants                     

                                8.2.4 Threat of Substitute Products and Services               

                                8.2.5 Competitive Rivalry within the Industry                      

9. Market Leaders' Analysis                                                        

                9.1 BoehringerIngelheim GmbH                               

                                9.1.1 Overview                

                                9.1.2 Product Analysis                   

                                9.1.3 Strategic Evaluation and Operations                            

                                9.1.4 Financial analysis                  

                                9.1.5 Legal issues                            

                                9.1.6 Recent Developments                       

                                9.1.7 SWOT analysis                       

                                9.1.8 Analyst View                          

                9.2 Hoffman-La Roche                                  

                9.3 Pfizer Inc.                                    

                9.4 GlaxoSmitKline                                         

                9.5 Eli Lilly and Company                                             

                9.6 AstrazenecaPlc                                         

                9.7 Sanofi-Aventis                                          

                9.8 Agennix AG                                

10. Competitive Landscape                                                         

                10.1 Market share analysis                                          

                10.2 Merger and Acquisition Analysis                                     

                10.3 Agreements, collaborations and Joint Ventures                                       

                10.4 New Product Launches                                       

11. Expert Opinions                                                        

                11.1 Market Outlook                                     

                11.2 Investment Opportunities                                 

Appendix                                                           

                a) List of Tables                                

                b) List of Figures                      

  1. North America Lung Cancer Therapeutics Market, By Region, From 2022 - 2027 (USD Billion)
  2. North America Lung Cancer Therapeutics Market, By Treatment Type, From 2022 - 2027 (USD Billion)
  3. North America Chemotherapy Market, By Region, From 2022 - 2027 (USD Billion)
  4. North America Radiotherapy Market, By Region, From 2022 - 2027 (USD Billion)
  5. North America Other Lung Cancer Therapeutic Drugs Market, By Region, From 2022 - 2027 (USD Billion)
  6. United States Lung Cancer Therapeutics Market, By Treatment Type, From 2022 - 2027 (USD Billion)
  7. Canada Lung Cancer Therapeutics Market, By Treatment Type, From 2022 - 2027 (USD Billion)
  8. North America Lung Cancer Chemotherapy Market, By Drug Type, From 2022 - 2027 (USD Billion)
  9. North America Cisplatin Market, By Region, From 2022 - 2027 (USD Billion)
  10. North America Taxol Market, By Region, From 2022 - 2027 (USD Billion)
  11. North America Navelbine Market, By Region, From 2022 - 2027 (USD Billion)
  12. North America Camptosar Market, By Region, From 2022 - 2027 (USD Billion)
  13. North America Alimta Market, By Region, From 2022 - 2027 (USD Billion)
  14. United States Lung Cancer Chemotherapy Market, By Drug Type, From 2022 - 2027 (USD Billion)
  15. Canada Lung Cancer Chemotherapy Market, By Drug Type, From 2022 - 2027 (USD Billion)
  16. North America Lung Cancer Radiotherapy Market, By Type, From 2022 - 2027 (USD Billion)
  17. North America External Beam Market, By Region, From 2022 - 2027 (USD Billion)
  18. North America Internal Beam Market, By Region, From 2022 - 2027 (USD Billion)
  19. North America Systemic Market, By Region, From 2022 - 2027 (USD Billion)
  20. United States Lung Cancer Radiotherapy Market, By Type, From 2022 - 2027 (USD Billion)
  21. Canada Lung Cancer Radiotherapy Market, By Type, From 2022 - 2027 (USD Billion)
  22. North America Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2022 - 2027 (USD Billion)
  23. North America Abraxane Market, By Region, From 2022 - 2027 (USD Billion)
  24. North America Avastin Market, By Region, From 2022 - 2027 (USD Billion)
  25. North America Crizotinib Market, By Region, From 2022 - 2027 (USD Billion)
  26. North America Docetaxel Market, By Region, From 2022 - 2027 (USD Billion)
  27. North America Gefitinib Market, By Region, From 2022 - 2027 (USD Billion)
  28. United States Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2022 - 2027 (USD Billion)
  29. Canada Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample